An interventional study of Alcohol and Placebo in Post-Traumatic Stress Disorder and Alcohol Drinking, sponsored by University of Texas at Austin. Recruiting at 1 site in United States. Open to participants aged 21 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-15.
Sponsored by University of Texas at Austin · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies in Stress Disorders, Post-Traumatic by University of Texas at Austin — 6 open to participants now, 6 under way, none of them phase 3. Stress Disorders, Post-Traumatic · University of Texas at Austin.
Among the 20 studies in Stress Disorders, Post-Traumatic by University of Texas at Austin, this one is the 2nd largest by planned enrollment, is the only one that started in 2023, is one of 15 with no phase, and was the 16th registered.
2,689 studies on the registry are indexed under Stress Disorders, Post-Traumatic; 605 are open to participants now.
Browse Stress Disorders, Post-Traumatic studies →6 of the 20 studies in Stress Disorders, Post-Traumatic by University of Texas at Austin are open now, in 1 country. Recruiting first, the newest first:
University of Texas at Austin · Sites in United States
Ages 18–46 · Women only
University of Texas at Austin · Sites in United States
Ages 18–65
University of Texas at Austin · Sites in United States
Ages 18–65
University of Texas at Austin · Sites in United States
Ages 18+
University of Texas at Austin · Sites in United States
Ages 18–50 · Healthy volunteers
By country, each count listing its studies:
Of the 416 Stress Disorders, Post-Traumatic studies recruiting now, 188 (45%) set no upper age limit and 202 (49%) stop at 75 or younger; 62 take children under 18; 88 take healthy volunteers.
This study: 21 Years to 60 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 3 · Phase 3 1
First in 2005; this study’s year is marked. 1 started in 2023.
This study's planned enrollment of 200 is above the median of 69 across 2,203 interventional studies indexed under Stress Disorders, Post-Traumatic.
Median enrollment 65 across the 20 interventional studies. Of the 9 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
University of Texas at Austin is the lead sponsor of 328 studies on the registry; 79 are open to participants now.
Of its 10 completed or terminated interventional studies of FDA-regulated products, 5 (50%) have results posted.
2 of the studies in Stress Disorders, Post-Traumatic by University of Texas at Austin that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07060144University of Texas at AustinCognitive Processing Therapy (CPT) for Perinatal Posttraumatic Stress Disorder (PTSD) | 2027-05 |
| NCT05427708University of Texas at AustinRespiratory Training in the Treatment of Transdiagnostic Pathological Anxiety | 2027-05 |
Add all 2 to your calendar (.ics) → With an account.
Among the 20 studies in Stress Disorders, Post-Traumatic by University of Texas at Austin, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Individuals with posttraumatic stress disorder (PTSD) have greater prevalence of alcohol use disorders (AUDs), with this comorbidity associated with worse illness outcomes, yet there remains limited mechanistic understanding of how PTSD confers risk for AUD. Understanding risk factors that associate with and predict the development of AUDs in PTSD could inform interventions and prevention efforts to reduce the rate of this comorbidity and improve outcomes of both disorders. Identifying predictors of risk requires longitudinal studies in PTSD aimed at capturing the mechanisms leading to the emergence of AUDs. There is growing evidence PTSD is related to biased decision-making during approach-avoidance conflict. Alcohol is also suggested to alter approach-avoidance decision-making. AUDs and acute alcohol intoxication is associated with a bias to seek out reward despite the possibility of threat (e.g., contributing to relapse following alcohol cue exposure and risky behavior during intoxication respectively). Alcohol-induced changes in approach-avoidance decision-making have not been investigated in the context of PTSD, but emerging data support the investigators' hypothesis that an interaction between alcohol and approach-avoidance conflict in PTSD may occur and contribute to risk for alcohol misuse and development of alcohol problems. No current data, cross-sectional or longitudinal, have tested the role of alcohol-induced changes in approach-avoidance conflict as a mechanism of risk for AUD among individuals with PTSD. To address this gap, the investigators propose to leverage the group's expertise in placebo-controlled alcohol administration procedures, longitudinal modeling, functional neuroimaging, and computational neuroscience approaches to investigate the effects of acute alcohol on approach-avoidance decision-making and mediating changes in multivariate neurocircuitry patterns in limbic, striatal, and salience networks.
The proposed study will test the conceptual model positing that acute alcohol alters the relative bias in computational mechanisms for threat vs reward, thereby decreasing avoidance to threat and increasing approach to reward in adults with PTSD, and through this mechanism increases risk for heavier alcohol use over time. Research aims are to identify alcohol-induced changes in approach-avoidance decision-making and mediating neural networks that predict alcohol use and symptoms of AUDs over a one-year follow-up period in adults with PTSD, compared to adults with interpersonal violence exposure but no PTSD and healthy comparison adults. Essential to successfully improving clinical prognosis in PTSD are research results that enable better prediction, diagnosis, and treatment based on the individual. There is a paucity of human clinical research investigating interactions between acute alcohol exposure and PTSD that may drive risk for development of AUDs following trauma. Data could identify brain and behavioral mechanisms explaining how alcohol alters an important domain of PTSD contributing to risk for alcohol misuse and development of alcohol problems. Results could pave way for development of novel behavioral and pharmacological methods to treat PTSD and decrease risk for developing comorbid AUDs.
Inclusion criteria for all participants:
Inclusion criteria for PTSD participants:
- Meeting diagnostic criteria for PTSD, confirmed by structured interview
For all subjects exclusion criteria include:
Additional exclusion criteria for participants in PTSD and IPV-exposed but no PTSD groups:
Additional exclusion criteria for participants in IPV-exposure but no PTSD group:
- history of PTSD
Additional exclusion criteria for healthy comparison subjects also include:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will drink beverages containing alcohol.
Other: Alcohol
Participants will drink beverages containing a very low dose of alcohol (placebo condition).
Other: Placebo
Participants will consume beverages containing alcohol.
Participants will consume beverages containing a very low dose of alcohol (placebo condition).
ratio of approach to avoidance choices
the number of trials on which individuals chose to avoid vs approach will be quantified during the task and compared between placebo and alcohol conditions
Time frame: 1 week
changes in dorsal anterior cingulate cortex activation
the degree of activation on high conflict trials (relative to low conflict trials) on the task in the dorsal anterior cingulate will be quantified and compared between the placebo and alcohol conditions
Time frame: 1 week
Relations between ratio of approach to avoidance choices with alcohol use over a one-year follow-up
The relationship between the number of trials on which individuals chose to avoid vs approach during the alcohol session with alcohol use over a one-year follow up will be modeled. Number of drinks consumed per day over the course of the follow-up year will be used to calculate Area Under the Curve (AUC), with AUC as the dependent variable.
Time frame: 1 year
Relations between changes in dorsal anterior cingulate cortex activation with alcohol use over a one-year follow-up
The relationship between the degree of activation on high conflict trials (relative to low conflict trials) on the task in the dorsal anterior cingulate during the alcohol session with alcohol use over a one-year follow up will be modeled. Number of drinks consumed per day over the course of the follow-up year will be used to calculate Area Under the Curve (AUC), with AUC as the dependent variable.
Time frame: 1 year
Plan to share: Yes — After study completion and publication of finding, functional neuroimaging data and behavior data collected following alcohol and placebo conditions will be shared.
Supporting information: Statistical analysis plan
Time frame: We will complete all our analyses and publish results and methodologies in scientific journals before the data are available to the research community. Data will be made available following 6 months after publication.
Access criteria: We will be collecting identifying information. Even though the final dataset will be stripped of identifiers prior to release for sharing, we believe that there remains the possibility of deductive disclosure of subjects with unusual characteristics. Thus, we will make the data and associated documentation available to users only under a data-sharing agreement that provides for: (1) a commitment to using the data only for research purposes and not to identify any individual participant; (2) a commitment to securing the data using appropriate computer technology; and (3) a commitment to destroying or returning the data after analyses are completed.
No publications or documents are linked to this record.
Started Oct 2023 (actual). Primary completion is estimated for May 2028, 55 months after the start.
Of 1,066 non-industry interventional studies with no phase under Stress Disorders, Post-Traumatic, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 53. This study's planned 55 months is above that.
Counting every sponsor, half of 1,094 studies reached it within 35 months; a quarter within 17 and three quarters within 53.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Stress Disorders, Post-Traumatic →
University of Texas at Austin →